Interclean Shanghai

CORE Diagnostics and CanCertain Healthcare Join Forces to Revolutionize Cancer Treatment

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

EU Begins Revision of Medical Device...

The European Commission has gone on to initiate a...

FDA Seeks Opinion on AI-Enabled Medical...

The U.S. Food and Drug Administration (US FDA) is...

FDA Approves Zenix Monitor-Defibrillator from ZOLL

ZOLL®, which happens to be an Asahi Kasei company...

MHRA in the UK Accelerates AI...

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

CORE Diagnostics, a leading provider of advanced diagnostics solutions, is excited to announce a strategic collaboration with CanCertain Healthcare, a pioneering healthcare company dedicated to enhancing cancer treatment outcomes. This partnership marks a significant milestone in the field of oncology, aimed at revolutionizing how cancer patients receive personalized treatment.

Cancer is a daunting diagnosis that raises numerous questions and concerns for patients and their families. Questions about treatment options, cost, success rates, and potential side effects can create immense emotional distress. Oncologists are tasked with the challenging responsibility of swiftly determining the most effective treatment plans for each patient.

CanCertain Healthcare has set out to address this challenge with its groundbreaking CanCertain® test. By providing valuable insights into the sensitivity or resistance of a patient’s tumor to specific cancer drugs, this innovative diagnostic tool empowers oncologists to make more informed treatment decisions. This not only saves precious time but also reduces the financial burden of ineffective treatments.

“The CanCertain® test is a game-changer in the field of oncology,” states Dr. Shivani Sharma, Vice President of Pathology Services & Lab Director, CORE Diagnostics. “It allows us to identify the most effective drugs for a patient’s unique tumor and consider their individual immunity and drug resistance. By doing so, we minimize the need for multiple rounds of different drugs, safeguard the patient’s immune system, and significantly improve the chances of successful cancer treatment.”

This collaboration between CORE Diagnostics and CanCertain Healthcare is poised to reshape cancer care by bringing cutting-edge diagnostic capabilities to the forefront of oncology. The focus of this partnership is primarily on empowering healthcare providers and oncologists rather than direct patient interactions. Doctors will be equipped with the vital information needed to prescribe the most appropriate and effective treatments, optimizing the patient’s journey toward recovery.

Mr. Dinesh Chauhan, CEO, CORE Diagnostics, comments, “CORE Diagnostics is proud to partner with CanCertain Healthcare to enhance the precision and effectiveness of cancer treatment. Our combined expertise will not only benefit patients but also healthcare providers who strive to deliver the best possible care.”

CanCertain Healthcare’s mission aligns with CORE Diagnostics commitment to advancing healthcare through innovation. Together, they aim to improve patient outcomes, reduce the financial burden of cancer treatment, and provide hope to those affected by this devastating disease.

As we move forward, CORE Diagnostics and CanCertain Healthcare are excited about the transformative impact this collaboration will have on the field of oncology. By harnessing the power of advanced diagnostics, they aim to give cancer patients a fighting chance and make personalized cancer treatment a reality.

Latest stories

Related stories

EU Begins Revision of Medical Device Regulatory Framework

The European Commission has gone on to initiate a...

FDA Seeks Opinion on AI-Enabled Medical Devices Regulation

The U.S. Food and Drug Administration (US FDA) is...

FDA Approves Zenix Monitor-Defibrillator from ZOLL

ZOLL®, which happens to be an Asahi Kasei company...

MHRA in the UK Accelerates AI Rollout in the NHS

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »